Ann: Positive Preclincal Data on Efficacy in New Indication, page-5

This is really fantastic news for shareholders.....

"Chief Executive Officer, Dr Liz Dallimore said: “We are very encouraged by these results on the efficacy of ARG-007 in the 4-VO animal model. Brain injury resulting from a reduction in blood flow to the brain following cardiac arrest and cardiac surgery can result in long-term neurological deficits in these patients. This data provides further confirmation that our lead candidate, ARG-007, can provide neuroprotection in applications beyond focal stroke, HIE and TBI. We will now consider ways to progress the results of this study into clinical studies.”

We talked yesterday about how beyond stroke, ARG-007, licensed to cure, could potentially be used for traumatic brain injury (TBI) Hypoxic-ischemic encephalopathy (HIE) AND now we have another market to consider.... cerebral ischaemia following cardiac arrest and in certain cardiac surgeries.

Obviously the more applications this drug potentially has the higher the potential revenues and the better for us shareholders and of course patients who might suffer from these medical afflictions in the future!

Great work Argenica.